Health economic comparisons of rofecoxib versus conventional nonsteroidal antiinflammatory drugs for osteoarthritis in the United Kingdom

摘要: SUMMARYConventional NSAIDs cause major gastrointestinal complications and minor symptoms. Most publications on the economic implications of NSAID gastropathy have examined ulceration rates with endoscopy, adjusted for ulcers that are "silent," i.e. never require clinical treatment. Silent ulcer used range from 40% to 85%. Decision analytic modeling was done examine switching all OA patients currently treated conventional rofecoxib, perspective National Health Service.Analysis 1 based investigator observed perforations, symptomatic ulcers, bleeds (PUBs). Analyses 2 3 were endoscopic adjustments silent 85% 40%, respectively. Analysis showed rofecoxib would cost NHS £0.32 extra per patient day year life saved estimated at £15,647, a figure within accepted benchmarks cost-effectiveness ...